| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594285 | American Heart Journal | 2017 | 23 Pages |
Abstract
In a large group of elderly patients enrolled in the EUROMAX and HORIZONS-AMI trials, bivalirudin was associated with lower 30-day rates of non-CABG major bleeding, subacute ST and NACE, with similar 30-day rates of acute ST and mortality.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Khalid MD, Gerrit-Jan A. MD, Thomas PhD, Philippe Gabriel MD, PhD, Christian W. MD, PhD, Arnoud MD, PhD, Roxana MD, Efthymios N. MD, Debra PhD, Gregg W. MD, Jurriën M. MD, PhD,